| pubmed-article:21035484 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C0001074 | lld:lifeskim |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C0018870 | lld:lifeskim |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:21035484 | lifeskim:mentions | umls-concept:C1998548 | lld:lifeskim |
| pubmed-article:21035484 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21035484 | pubmed:dateCreated | 2011-4-18 | lld:pubmed |
| pubmed-article:21035484 | pubmed:abstractText | We have isolated cell with the cancer initiating cell (CIC) phenotype from PC3 cells. The PC3/(CIC) cells are more resistant than the PC3/(BC) cells to chemotherapeutic drugs such as docetaxel which is used to treat prostate cancer. Thus these prostate CICs could lay dormant and persist even after chemotherapeutic drug treatment. Then when the chemotherapeutic drug is removed, they could potentially repopulate the original tumor site or metastize to a distant site. However, the prostate CICs were not significantly more resistant to drugs which target EGFR, NF-?B, Smo and the natural product genistein. Interesting the prostate CICs could be rendered more sensitive to docetaxel by inclusion of suboptimal doses of genistein, cyclopamine, and EGFR inhibitors. In contrast, addition of suboptimal amounts of genistein, cyclopamine, or EGFR inhibitors did not increase the sensitivity of the PC/(BC) cells to docetaxel. Similar results were observed when combination experiments were performed with cyclopamine and suboptimal doses of either genistein or docetaxel. The BC cells are usually more rapidly proliferating than the CICs. Thus the CICs are not as sensitive to docetaxel which targets replication. In contrast, the CICs could be rendered sensitive to docetaxel or cyclopamine by co-treatment with certain other drugs, including the natural product genistein which is present in the human diet of many people, especially Asians. Genistein is by itself only weakly toxic to prostate and other cancer cells. That is probably one of the big reasons that it can be used as a dietary supplement for prostate and breast cancers. It is clear from our studies that low doses of genistein can increase the sensitivity of prostate CICs to drugs such as docetaxel and cyclopamine, two drugs either used or under consideration for prostate cancer therapy. | lld:pubmed |
| pubmed-article:21035484 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21035484 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21035484 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21035484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21035484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21035484 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21035484 | pubmed:issn | 1873-2437 | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:McCubreyJames... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:FranklinRicha... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:LaidlerPiotrP | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:SteelmanLinda... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:ChappellWilli... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:KempfC RuthCR | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:AbramsStephen... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:LongJacquelyn... | lld:pubmed |
| pubmed-article:21035484 | pubmed:author | pubmed-author:SattlerJennif... | lld:pubmed |
| pubmed-article:21035484 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21035484 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:21035484 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21035484 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21035484 | pubmed:pagination | 152-62 | lld:pubmed |
| pubmed-article:21035484 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:meshHeading | pubmed-meshheading:21035484... | lld:pubmed |
| pubmed-article:21035484 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21035484 | pubmed:articleTitle | Targeting the cancer initiating cell: the Achilles' heel of cancer. | lld:pubmed |
| pubmed-article:21035484 | pubmed:affiliation | Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA. mccubreyj@ecu.edu | lld:pubmed |
| pubmed-article:21035484 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21035484 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
